Steve Tutewohl - Feb 1, 2022 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Role
Chief Operating Officer
Signature
/s/ Jonathan Weinberg, Attorney-in-fact
Stock symbol
EVH
Transactions as of
Feb 1, 2022
Transactions value $
-$60,100
Form type
4
Date filed
2/1/2022, 04:40 PM
Previous filing
Sep 2, 2021
Next filing
Feb 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVH Class A Common Stock Options Exercise $88.1K +6.31K +6.28% $13.95 107K Feb 1, 2022 Direct F1, F2
transaction EVH Class A Common Stock Sale -$148K -6.31K -5.91% $23.47 101K Feb 1, 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVH Class A Common Stock Option (right to buy) Options Exercise $0 -6.31K -100% $0.00* 0 Feb 1, 2022 Class A Common Stock 6.31K $13.95 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021.
F2 Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.80, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The Class A Common Stock Options exercised vested on February 1, 2022.